| Cheng, Ying |
Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury |
|
|
| Recruiting | 4 | 165 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention | The First Affiliated Hospital of Dalian Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anqing Municipal Hospital, Henan Cancer Hospital, Wuhan Union Hospital, China, Peking University Shougang Hospital, Chinese PLA General Hospital, Liaoning Tumor Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Henan Provincial People's Hospital, Shanxi Provincial Cancer Hospital, Beijing Sanhuan Cancer Hospital, Hebei Medical University Fourth Hospital, Tongji Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Bethune Charitable Foundation | Cancer Treatment Induced Thrombocytopenia | 06/24 | 08/24 | | |
TRACES, NCT04902885: Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients |
|
|
| Completed | 3 | 95 | RoW | Trilaciclib, carboplatin, etoposide，or Topotecan, Trilaciclib plus chemotherapy, placebo, carboplatin, etoposide，or Topotecan, placebo plus chemotherapy | Jiangsu Simcere Pharmaceutical Co., Ltd., G1 Therapeutics, Inc. | Extensive-stage Small-cell Lung Cancer | 12/21 | 12/22 | | |
|
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
RATIONALE-312, NCT04005716: Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer |
|
|
| Completed | 3 | 457 | RoW | Tislelizumab, Carboplatin /Cisplatin, Etoposide, Carboplatin / Cisplatin, Etoposide | BeiGene | Small Cell Lung Cancer | 04/23 | 12/23 | | |
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer |
|
|
| Recruiting | 3 | 35 | RoW | Mirvetuximab Soravtansine, IMGN853, MIRV | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 04/23 | 12/23 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
HER2CLIMB-02, NCT03975647: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
|
|
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc. | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
NCT06247605: A Phase IIII Study of AL8326 in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 243 | RoW | AL8326 tablets, AL8326, placebo | Advenchen Laboratories Nanjing Ltd. | Small Cell Lung Carcinoma | 07/28 | 07/29 | | |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06498479: ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 460 | RoW | HS-20093, Topotecan | Hansoh BioMedical R&D Company | Small Cell Lung Cancer | 09/26 | 05/27 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT02584478: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) |
|
|
| Active, not recruiting | 3 | 294 | Europe, US, RoW | AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol | Advenchen Laboratories, LLC | Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma | 10/24 | 12/24 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
| Recruiting | 3 | 482 | Europe, US, RoW | HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI) | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Limited-Stage Small Cell Lung Cancer | 07/25 | 12/26 | | |
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) |
|
|
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
NCT05204628: A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib |
|
|
| Not yet recruiting | 3 | 238 | RoW | XZP-3621, Crizotinib | Xuanzhu Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 05/25 | 07/25 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 350 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04687241: Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations |
|
|
| Active, not recruiting | 3 | 192 | RoW | Almonertinib, HS-10296, Placebo Almonertinib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 07/24 | 01/29 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
|
|
| Recruiting | 2/3 | 445 | RoW | PM8002, Platinum, Atezolizumab, Etoposide | Biotheus Inc. | SCLC | 06/25 | 12/25 | | |
NCT02171325: Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment |
|
|
| Recruiting | 2 | 54 | RoW | irinotecan | Guangdong Association of Clinical Trials | Small Cell Lung Cancer | 06/21 | 06/21 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors |
|
|
| Terminated | 2 | 86 | RoW | Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
| Completed | 2 | 150 | US, RoW | Paclitaxel, Afuresertib, LAE002 | Laekna Limited | Platinum-resistant Ovarian Cancer | 07/23 | 06/24 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
NCT05863325: A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 80 | RoW | HB1801, Taxotere | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 03/24 | 09/24 | | |
NCT05354700: A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 20 | RoW | HLX07, HLX10, carboplatin and etoposide | Shanghai Henlius Biotech | Small-cell Lung Cancer | 03/24 | 05/24 | | |
NCT05879068: A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC |
|
|
| Recruiting | 2 | 99 | RoW | PM8002, Paclitaxel | Biotheus Inc. | SCLC | 04/24 | 04/26 | | |
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 99 | US, RoW | Sutetinib Maleate Capsule, Sutetinib | Teligene US | Non-small Cell Lung Cancer | 08/24 | 02/25 | | |
| Not yet recruiting | 2 | 42 | RoW | Neratinib tablets, Epilepsy | Convalife (Shanghai) Co., Ltd. | NSCLC | 12/24 | 12/25 | | |
NCT05482087: A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC |
|
|
| Not yet recruiting | 2 | 190 | RoW | XZP-3621 | Xuanzhu Biopharmaceutical Co., Ltd. | ALK-positive NSCLC | 05/25 | 07/25 | | |
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement |
|
|
| Recruiting | 2 | 120 | Europe, Japan, US, RoW | TAS-120, Futibatinib | Taiho Oncology, Inc. | Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement | 06/25 | 06/26 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT05924841: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 100 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Small Cell Lung Cancer | 11/25 | 11/25 | | |
| Recruiting | 2 | 184 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 09/25 | 11/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib |
|
|
| Not yet recruiting | 2 | 54 | RoW | ABSK043 in combination with Firmonertinib | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer With EGFR Mutation | 06/27 | 06/28 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
NCT05918107: A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM |
|
|
| Recruiting | 2 | 55 | RoW | PM8002, Pemetrexed, Cisplatin, Carboplatin | Biotheus Inc. | MPM | 06/26 | 06/26 | | |
NCT06233292: A Study of ZG005 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 484 | RoW | ZG005 Powder for Injection, ZG005 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumors | 01/26 | 01/26 | | |
| Recruiting | 1/2 | 180 | RoW | AST-001 | Ascentawits Pharmaceuticals, Ltd | Solid Tumor, Pancreatic Cancer | 08/27 | 08/27 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor |
|
|
| Terminated | 1/2 | 7 | RoW | TJ1133 Injection | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
NCT05000684: Study of JS004 Combined With Toripalimab for Advanced Lung Cancer |
|
|
| Recruiting | 1/2 | 66 | RoW | JS004 in combination with toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Lung Cancer | 08/23 | 08/24 | | |
HLX301, NCT05390528: A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of (TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody | Shanghai Henlius Biotech | Advanced Tumors, Lymphoma, Metastatic Tumors | 09/23 | 12/24 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
NCT05383482: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 |
|
|
| Active, not recruiting | 1/2 | 22 | RoW | Afuresertib, LAE002, Nab paclitaxel, Docetaxel, Sintilimab | Laekna Limited | Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma | 06/24 | 12/25 | | |
NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 59 | US, RoW | IMP4297(senaparib), temozolomide | Impact Therapeutics, Inc. | Advanced Solid Tumours, Small Cell Lung Cancer | 04/24 | 04/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05478785: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 126 | RoW | Cisplatin micelle injection (HA132) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Malignant Solid Tumors | 12/24 | 08/25 | | |
AK104-212, NCT05505825: A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 36 | RoW | AK104 IV infusion；Chiauranib oral | Akeso, Chipscreen Biosciences, Ltd. | SCLC,Extensive Stage | 12/24 | 01/25 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 354 | US, RoW | PRO1184, PRO1184 intravenous infusion of PRO1184 | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 10/25 | 04/26 | | |
NCT05675605: A Study of TY-1091 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 248 | RoW | TY-1091 | TYK Medicines, Inc | RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms | 06/25 | 12/25 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 168 | RoW | SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/26 | 06/26 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TQB2858-I-01, NCT04805060: A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors |
|
|
| Recruiting | 1 | 30 | RoW | TQB2858 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminal Malignant Tumors | 12/21 | 12/25 | | |
NCT05162469: A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 100 | RoW | SHR-1909 injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Malignant Cancer | 12/22 | 03/23 | | |
NCT04672356: A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer |
|
|
| Completed | 1 | 19 | RoW | IBI939, Sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Lung Cancer | 01/23 | 06/23 | | |
NCT04672369: A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC |
|
|
| Completed | 1 | 42 | RoW | IBI939, Sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Lung Cancer | 01/23 | 06/23 | | |
NCT04672928: A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies |
|
|
| Completed | 1 | 20 | RoW | paclitaxel, IBI318 | Innovent Biologics (Suzhou) Co. Ltd. | Small Cell Lung Carcinoma | 01/23 | 01/23 | | |
PIANO, NCT03491631: Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 23 | RoW | SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib | Jiangsu HengRui Medicine Co., Ltd. | Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant | 06/23 | 09/23 | | |
NCT04991129: The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer |
|
|
| Recruiting | 1 | 66 | RoW | WJ01024 | Suzhou Junjing BioSciences Co., Ltd. | Advanced Hematologic Malignancies, Advanced Solid Tumors | 06/25 | 04/26 | | |
| Active, not recruiting | 1 | 297 | RoW | FS-1502 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Solid Tumor, Breast Cancer | 04/24 | 06/25 | | |
NCT04412616: ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies |
|
|
| Recruiting | 1 | 60 | US, RoW | ZZ06 | Changchun Intellicrown Pharmaceutical Co. LTD, Covance | Advanced EGFR Positive Solid Tumor | 12/23 | 04/24 | | |
NCT05145179: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors |
|
|
| Not yet recruiting | 1 | 162 | NA | SSGJ-705 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Receptor, ErbB-2 | 12/23 | 06/24 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/24 | 12/24 | | |
NCT05430386: Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1 | 174 | RoW | HS-10241, Almonertinib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 12/23 | 12/23 | | |
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 164 | US, RoW | ABSK112, EGFR Exon20 inhibitor | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer | 03/27 | 03/28 | | |
NCT06235983: A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | LY3537982, Olomorasib | Eli Lilly and Company | Advanced Solid Tumors | 01/25 | 01/26 | | |
NCT05504278: Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation |
|
|
| Recruiting | 1 | 144 | RoW | pemetrexed, cis-platinum, Sintilimab, IBI308, IBI351, GFH925, carboplatin | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Non-Small Cell Lung Cancer | 05/24 | 07/27 | | |
| Recruiting | 1 | 80 | RoW | SHR-4849 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/26 | 12/26 | | |
NCT05277454: Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT |
|
|
| Recruiting | 1 | 113 | RoW | HMPL-653 | Hutchison Medipharma Limited | Advanced Malignant Solid Tumors, TGCT | 06/24 | 04/25 | | |
NCT05690581: Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies |
|
|
| Recruiting | 1 | 146 | RoW | CM369 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors and Hematologic Malignancies | 06/24 | 04/25 | | |
NCT04001777: A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients |
|
|
| Recruiting | 1 | 80 | RoW | APG-1252, APG-1252 for injection, Osimertinib Mesylate Tablets, AZD9291 | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | EGFR Positive Non-small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. |
|
|
| Recruiting | 1 | 75 | RoW | TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Colorectal Cancer | 03/25 | 07/25 | | |
NCT06032936: BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations |
|
|
| Terminated | 1 | 4 | RoW | BBP-398, IACS-15509, osimertinib | LianBio LLC | NSCLC | 03/24 | 03/24 | | |
| Xu, Guiying |
NCT04967976: Breast Mesh Used in Two-staged Breast Reconstruction |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | TiLoop Bra mesh in expander-implant breast reconstrution, sub-pectoral expander-implant breast reconstruction | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer, Radiation, Breast Reconstruction, Synthetic Mesh | 08/23 | 08/26 | | |
